SCHEMBL3664366

SCHEMBL3664366

CC=CC(CC(=O)O)c1ccc(O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 4/20 0.42
ESR1 P03372 7/20 0.38
ESR2 Q92731 6/20 0.38
LMNA P02545 2/20 0.37
CYP1A2 P05177 1/20 0.37
PGR P06401 1/20 0.37
CHRM2 P08172 1/20 0.37
CYP3A4 P08684 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
AR P10275 1/20 0.37
CYP2D6 P10635 1/20 0.37
MAPT P10636 1/20 0.37
CHRM1 P11229 1/20 0.37
CYP2C9 P11712 1/20 0.37
ALOX15 P16050 1/20 0.37
DRD1 P21728 1/20 0.37
TBXA2R P21731 1/20 0.37
PTGS1 P23219 1/20 0.37
SLC6A2 P23975 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3667777 1.00 FFAR1 (0.42) FFAR1ESR1ESR2LMNACYP1A2
SCHEMBL3667776 1.00 FFAR1 (0.42) FFAR1ESR1ESR2LMNACYP1A2
SCHEMBL3664365 1.00 FFAR1 (0.42) FFAR1ESR1ESR2LMNACYP1A2
SCHEMBL28442232 1.00 FFAR1 (0.42) FFAR1ESR1ESR2LMNACYP1A2
SCHEMBL8225433 0.86 GABBR2 (0.46) FFAR1LMNACYP2D6MAPTCYP2C19
SCHEMBL3871999 0.83 FFAR1 (0.40) FFAR1ESR1ESR2LMNACYP1A2
SCHEMBL3661178 0.83 FFAR1 (0.40) FFAR1ESR1ESR2LMNACYP1A2
SCHEMBL3871994 0.83 FFAR1 (0.40) FFAR1ESR1ESR2LMNACYP1A2
SCHEMBL3661179 0.83 FFAR1 (0.40) FFAR1ESR1ESR2LMNACYP1A2
SCHEMBL3869153 0.82 ESR1 (0.42) ESR1ESR2LMNACYP1A2PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111423408-A Compound preparation for preventing or treating metabolic diseases 现代药品株式会社 2020-07-17 CN disclosed
CN-106715409-A Complex preparation for preventing or treating metabolic diseases comprising novel 3- (4- (benzyloxy) phenyl) -4-hexenoic acid derivative and other active ingredients 现代药品株式会社 2017-05-24 CN disclosed
EP-2139843-B1 SUBSTITUTED BIPHENYL PHENOXY-, THIOPHENYL- AND AMINOPHENYLPROPANOIC ACID GPR40 MODULATORS AMGEN INC (US) 2013-12-25 EP disclosed
EP-2508503-A1 Spiro compounds and pharmaceutical use thereof Japan Tobacco, Inc. (JP) 2012-10-10 EP disclosed
EP-2139843-A1 SUBSTITUTED BIPHENYL PHENOXY-, THIOPHENYL- AND AMINOPHENYLPROPANOIC ACID GPR40 MODULATORS Amgen, Inc (US) 2010-01-06 EP disclosed
US-7572934-B2 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-08-11 US disclosed
US-20090111859-A1 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-04-30 US disclosed
WO-2008130514-A1 SUBSTITUTED BIPHENYL PHENOXY-, THIOPHENYL- AND AMINOPHENYLPROPANOIC ACID GPR40 MODULATORS AMGEN INC. (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111859-A1 Substituted biphenyl GPR40 modulators GPR119, GPR65, GPR55 FFAR1 18/4885ESR1 173/4885ESR2 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.